Quibim’s flagship solution, which uses biopsy data for training, has received 510(k) clearance for use in the United States of America. QP-Prostate’s pivotal validation included a standalone ...

SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

Clarity Pharma’s potentially lifesaving technology has shown in trials that it detects prostate cancer lesions at double the rate of current tech. The product is a copper-based imaging agent. It ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...